Pam Marcus, Ph.D.
Program Director, Clinical and Translational Epidemiology Branch

Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
9609 Medical Center Drive, Rm. 4E608, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)

Interest Areas

  • Cancer screening methodology
  • Cancer etiology
  • Surveillance for cancer recurrence
  • Health services research
  • Breast and lung cancer
  • Scientific mentoring and coaching
  • Scientific writing and editing


  • Ph.D. - Epidemiology
    University of North Carolina, Chapel Hill
  • M.S. - Preventive Medicine
    University of Wisconsin–Madison
  • M.S. - Statistics
    University of Wisconsin–Madison


  • Board-certified Editor in the Life Sciences


Dr. Pamela Marcus is a Program Director and Epidemiologist in the Epidemiology and Genomics Research Program's (EGRP) Clinical and Translational Epidemiology Branch (CTEB). She is an expert in assessment of cancer screening modalities and is currently studying surveillance for disease recurrence among cancer survivors treated with curative intent. She is on half-time detail with DCCPS’s Healthcare Delivery Research Program (HDRP), assisting with initiatives and grants that involve cancer screening, including the Breast Cancer Surveillance Consortium (BCSC) and the second round of the Population-based Research to Optimize the Screening Process (PROSPR) Initiative.

Dr. Marcus began her career at the NCI as a postdoctoral Cancer Prevention Fellow. From 1997 to 2011, she was a member of the Division of Cancer Prevention's Biometry Research Group. She worked on NCI's National Lung Screening Trial and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, two large randomized controlled trials examining the efficacy of various screening modalities. During that time, she published extensively on lung cancer screening. Dr. Marcus moved to the Applied Research Program (ARP) in NCI's Division of Cancer Control and Population Sciences (DCCPS) in 2011 to lead the PROSPR Initiative, an observational study of cancer screening processes in clinical settings. Dr. Marcus also worked with BCSC investigators to facilitate establishment of the BCSC Research Resource, a data and analysis resource available for free to the research community and the general public. She joined EGRP in August 2013 to expand the Program’s knowledge base in cancer screening and surveillance for recurrence and led efforts to explore precision cancer screening.

Dr. Marcus is EGRP’s Fellows Coordinator. She is also a member of NCI’s PDQ® Screening and Prevention Editorial Board.

Selected Publications

Marcus PM, Pashayan N, Church TR, et al. Population-based precision cancer: a symposium on evidence, epidemiology, and next steps. Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1449-1455.

Marcus PM, guest ed. The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the operations behind a herculean task. Rev Recent Clin Trials. 2015;10(3):172.

Marcus PM, Prorok PC, Miller AB, DeVoto EJ, Kramer BS. Conceptualizing overdiagnosis in cancer screening. J Natl Cancer Inst. 2015 Feb 6;107(4).

Marcus PM, Freedman AN, Khoury MJ. Targeted cancer screening in average-risk individuals. Am J Prev Med. 2015 Nov;49(5):765-771.

The National Lung Screening Research Team. Reduced lung cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.

Marcus PM, Gareen IF, Miller AB, Rosenbaum J, Keating K, Aberle DR, Berg CD. The National Lung Screening Trial's endpoint verification process: determining the cause of death. Contemp Clin Trials. 2011;32(6):834-40.

Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS. Extended lung cancer incidence follow-up in the Mayo Lung Project: additional support for overdiagnosis. J Natl Cancer Inst. 2006; 98:748-756.

Marcus PM, Bergstralh EJ, Fagerstrom RM, Fontana RS, Taylor W, Prorok PC. Lung cancer mortality in the Mayo Lung Project: the impact of extended follow-up. J Natl Cancer Inst. 2000;92:1308-1316.

Return to Top